Cwm LLC Sells 18,000 Shares of Organogenesis $ORGO

Cwm LLC lessened its holdings in shares of Organogenesis (NASDAQ:ORGO) by 28.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 45,894 shares of the company’s stock after selling 18,000 shares during the period. Cwm LLC’s holdings in Organogenesis were worth $168,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Organogenesis by 10.8% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company’s stock valued at $187,000 after purchasing an additional 4,239 shares in the last quarter. Farther Finance Advisors LLC bought a new position in Organogenesis in the 2nd quarter valued at about $35,000. Victory Capital Management Inc. bought a new position in Organogenesis during the 1st quarter worth $67,000. OMERS ADMINISTRATION Corp bought a new position in shares of Organogenesis during the first quarter worth approximately $77,000. Finally, Ieq Capital LLC bought a new position in shares of Organogenesis in the first quarter worth $79,000. 49.57% of the stock is currently owned by institutional investors.

Organogenesis Trading Down 0.5%

Shares of Organogenesis stock opened at $4.17 on Thursday. The firm has a market cap of $529.01 million, a PE ratio of -29.78 and a beta of 1.68. The stock has a 50 day moving average of $4.51 and a 200 day moving average of $4.19. Organogenesis has a 12 month low of $2.61 and a 12 month high of $6.71.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The business had revenue of $101.01 million for the quarter, compared to the consensus estimate of $104.75 million. Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%. Organogenesis has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ORGO. Cantor Fitzgerald boosted their price target on Organogenesis from $7.00 to $9.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. BTIG Research reiterated a “buy” rating and set a $7.00 target price on shares of Organogenesis in a research note on Friday, September 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Organogenesis in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $7.33.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.